Elevated ?-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors
| dc.authorid | 0000-0003-2209-7694 | |
| dc.contributor.author | Thapa, Simant Singh | |
| dc.contributor.author | Lal, Amos | |
| dc.contributor.author | Ömer, Abdulkadir | |
| dc.contributor.author | Trivedi, Nitin | |
| dc.date.accessioned | 2019-12-23T14:00:46Z | |
| dc.date.available | 2019-12-23T14:00:46Z | |
| dc.date.issued | 2019 | |
| dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | |
| dc.department | İstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER) | |
| dc.description.abstract | SGLT2 inhibitor (SGLT2i) class of medications are known to cause to euglycemic diabetic ketoacidosis (euDKA) as reported in the article by Lin et al. in your esteemed publication about this entity being reported for the first time in Taiwanese population.1 We wish to share the findings from our center to further expand the spectrum of findings associated with SGLT2i therapy. SGLT2i treatment in patients with preexisting atherosclerotic heart disease and those with high risk of cardiovascular events is associated with a reduction in cardiovascular (CV) mortality, heart failure hospitalizations, and death from any cause. | |
| dc.identifier.citation | Thapa, S. S., Lal, A., Ömer, A. ve Trivedi, N. (2019). Elevated ?-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors. Journal of the Formosan Medical Association, 118(10), 1473-1474. https://doi.org/10.1016/j.jfma.2019.04.021 | |
| dc.identifier.doi | 10.1016/j.jfma.2019.04.021 | |
| dc.identifier.endpage | 1474 | |
| dc.identifier.issn | 0929-6646 | |
| dc.identifier.issue | 10 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.startpage | 1473 | |
| dc.identifier.uri | https://doi.org/10.1016/j.jfma.2019.04.021 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/4621 | |
| dc.identifier.volume | 118 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.relation.ispartof | Journal of the Formosan Medical Association | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | Cardiovascular | |
| dc.subject | Euglycemic-Diabetic Ketoacidosis | |
| dc.subject | Ketonemia | |
| dc.subject | SGLT2 | |
| dc.title | Elevated ?-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors | |
| dc.type | Article |
